Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626 1629
This examiner grants 53% of resolved cases
Anna Grace Kuckla is positioned in Tech Center 1600 and Art Unit 1626, having processed 45 resolved cases. The examiner's allowance rate pct is 51.1, which establishes a nearly even split between allowed and abandoned cases in their portfolio. This 51.1 allowance rate pct suggests a rigorous examination process where applicants must be precise in their claim drafting and responses.
A notable aspect of this profile is the interview lift pct of 55.3, which represents a substantial increase in the likelihood of allowance following a formal discussion. This 55.3 lift suggests that interviews are a critical tool for overcoming rejections and reaching an agreement on patentable subject matter. In Art Unit 1626, the 55.3 interview lift pct indicates that verbal negotiation is significantly more effective than relying solely on written amendments.
The median days to allowance is 1247, providing a specific timeframe for the expected length of prosecution. Applicants should factor this 1247 median days into their long-term planning for intellectual property assets. The 51.1 allowance rate pct and the 45 resolved cases suggest a balanced environment where communication is key. The 1247 median days to allowance serves as a temporal guide for those working within Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | Final Rejection | Deciphera Pharmaceuticals, LLC |
| 18578617 | Compounds for Modulating Epithelial 15-(S)-Lipoxygenase-2 and Methods of Use for Same | Final Rejection | The Regents of the University of California |
| 18411753 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS | Non-Final OA | The Johns Hopkins University |
| 18034520 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | Non-Final OA | Emory University |
| 18722189 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Non-Final OA | Bayer Aktiengesellschaft |
| 17625023 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18258735 | PHOTOPATTERNED BIOMOLECULE IMMOBILIZATION TO GUIDE 3D CELL FATE IN NATURAL PROTEIN-BASED HYDROGELS | Non-Final OA | University of Washington |
| 18857689 | TEMPERATURE STABLE EMULSIONS | Non-Final OA | BEIERSDORF AG |
| 18208024 | COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER | Final Rejection | Hoffmann-La Roche Inc. |
| 18706615 | MEDIUM CHAIN DICARBOXYLIC ACIDS FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18867750 | TEAD Targeting Compounds and Methods Thereof | Non-Final OA | Agency for Science, Technology and Research |
| 18858534 | CHIRAL ARYL PROPIONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF, AND USE | Non-Final OA | SHIJIAZHUANG DISCOVERY MEDICINE TECHNOLOGY CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy